u/laila_wojcik

The three separate questions people ask here as though they were one.

paper_trail_paula is right that a rejected claim and a denied authorization are different animals.

Confused a rejected claim with a denied authorization for a month and pursued entirely the wrong process.

What did the denial actually say?

regional stock changes everything about transit

How many shipments does your figure cover?

That is a packaging observation, not a transit observation.

fridge_door_no is right about regional stock. It changes the shape of the distribution, not just the mean.

Agreed on keeping every form and date. When something goes wrong the paper trail is the whole case.

a rejected claim is not the same as a denied authorization

A private prescription is an independent route: it does not affect NHS list position, and it is not a step in the same pathway.

The online consultation asked me three questions, none of them about my history. I did not go ahead.

log what you did, not what you meant to do

Median transit is the useful statistic.

This is why the lane table is organised the way it is. The supplier is not the unit.

The document I was worried about turned out to be a re-issue with a later creation date. Asked, got the original, entirely ordinary.

Annotated the fortnight I changed training. Without that note the numbers around it would look like a mystery.

Disagree — that is your province’s formulary position and it does not carry to another.

redact your own name, never the batch details

gallbladder_gary has the distinction right — one is a fraction of the detector signal, the other is a fraction of the mass.

Asked QSC which lines they hold regionally before ordering and got a straight list back.

Agreed — and the decomposition matters. Most people are blaming the international leg for a last-mile problem.

I would not read a rounded figure as evasive. Plenty of documents round to one decimal as house style.

National regulatory approval establishes that a product may be sold. Whether any plan pays for it is a separate decision, and public drug plans are administered provincially.

Agreed on keeping letters. Dates are what make an appeal or a re-referral possible.

a total of 0.4% tells you less than four named impurities adding to 0.6%

Which nation, and which ICB if you are in England?

Correction: that is net peptide content, not purity. Different number, different meaning, and the document says so if you read the row label.

Concentrations can differ between products and between pharmacies.

Agreed — and keeping the letters with dates is what makes any later challenge possible.

Kept one line a week for 21 months. It was pointless for the first eight weeks and then it was the most useful document I owned.

a total of 0.4% tells you less than four named impurities adding to 0.6%

Disagree on this specific point. Two honest labs can resolve that impurity differently and report different numbers.

What is the one column you added late and wish you had from the start?

HPLC-UV and LC-MS answer different questions

Cosigning on discharge at goal. It catches people who have done everything right and did not know it was coming.

the related substances line is where the story is

Asked for the storage condition behind the stability statement. Got it in a sentence. It is a two-line email and almost nobody sends it.

GP said no and specialist said yes is a very common sequence

Missing entries recorded as blanks preserve the shape of the series. Dropping them silently makes the remaining points look more regular than they were.

Special authorization is a documented exception process with published criteria. Applications that answer those criteria explicitly, point by point, fare better than general clinical narratives.

The document I was worried about turned out to be a re-issue with a later creation date. Asked, got the original, entirely ordinary.

What does the method line actually say? Not the technique — the column and the gradient.

reship policy in writing before you order